Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | EVP Endocrine Business Unit | February 28, 2022 | August 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date February 28, 2022 · Filed August 25, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock,$.01 par valueSEC Table I · non-derivative | Direct | 576,690 |
Reported balance
After 2022-02-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-02-28 · Grant · Acquired 36,900 · Balance 576,690 F1: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2022 Filed Aug 24, 2022 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 15 | $3.84 | $57.60 |
DisclosureSEC source: 0001209191-22-047280 · doc4.xml · nonDerivative · entry 2 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,075 Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 4,600 | $3.85 | $17,713.22 |
DisclosureSEC source: 0001209191-22-047280 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,090 Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 10:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $2.93 | $14,650.00 |
DisclosureSEC source: 0001209191-22-043574 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,690 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2022 representing the maximum allowable under the Plan for this period. Read SEC document |
| July 31, 2022 Filed Aug 25, 2022 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 5,000 | $2.93 | $14,650.00 |
DisclosureSEC source: 0001209191-22-047423 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,690 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective July 31, 2022. Read SEC document |
| May 18, 2022 Filed May 21, 2022 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 4,789 | $3.19 | $15,276.91 |
DisclosureSEC source: 0001209191-22-031202 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,901 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2022 Filed May 26, 2022 00:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | OtherCommon Stock, $.01 Par Value | 4,789 | $3.19 | $15,276.91 |
DisclosureSEC source: 0001209191-22-031996 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,690 F1 · kind: This report corrects total amount of securities beneficially owned as no shares were withheld to satisfy the tax liability incident on 5/18/2022 for the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028679 · doc4.xml · nonDerivative · entry 2 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,690 F3 · shares: The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:01 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028679 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,690 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:01 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock,$.01 par value | 36,900 | $2.71 | $99,999.00 |
DisclosureSEC source: 0001209191-22-014102 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,690 Read SEC document |
| February 28, 2022 Filed Aug 25, 2022 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock,$.01 par value | 36,900 | $2.71 | $99,999.00 |
DisclosureSEC source: 0001209191-22-047428 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,690 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective February 28, 2022. The purchase was approved by the Company's Board of Directors. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 22:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 2,334 | $3.17 | $7,398.78 |
DisclosureSEC source: 0001209191-22-006415 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,320 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 10, 2022 02:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 1,804 | $3.17 | $5,718.68 |
DisclosureSEC source: 0001209191-22-008268 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,790 F1 · shares: The reporting person purchased shares through the Company's Employee Stock Purchase Plan on January 31, 2022. The amended number of shares purchased were limited by Section 423(b)(8) of the Code. Read SEC document |
| January 31, 2022 Filed Aug 25, 2022 01:00 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 1,804 | $3.17 | $5,718.68 |
DisclosureSEC source: 0001209191-22-047421 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · EVP Endocrine Business Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,790 F1 · kind: This Form 4 is being amended to correct the transaction code. The securities were purchased through the Company's Employee Stock Purchase Plan effective January 31, 2022. Read SEC document |
| August 27, 2021 Filed Aug 28, 2021 01:01 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 9,616 | $4.91 | $47,214.56 |
DisclosureSEC source: 0001209191-21-053770 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,986 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 00:00 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 5,000 | $2.99 | $14,950.00 |
DisclosureSEC source: 0001209191-21-049137 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,602 F1 · kind: The reporting person purchased shares through the Company's Employee Stock Purchase Plan effective July 31, 2021 representing the maximum allowable under the Plan for this period. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 79,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034451 · doc4.xml · nonDerivative · entry 2 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,602 F3 · shares: The restricted stock unit will vest on May 17, 2024 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 17, 2021. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 18, 2021 until May 17, 2024 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034451 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,602 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 23:57 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 34,602 | $2.89 | $99,999.78 |
DisclosureSEC source: 0001209191-20-062790 · doc4a.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,602 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:07 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048847 · doc4.xml · nonDerivative · entry 2 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,000 F3 · shares: The restricted stock unit will vest on May 22, 2023 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on August 27, 2020. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from August 27, 2020 until May 22, 2023 related to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 23:07 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 164,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048847 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. Read SEC document |
| November 14, 2018 Filed Dec 10, 2020 22:07 UTC | MANNKIND CORP MNKD · Entity 4792 | PurchaseCommon Stock, $0.01 Par Value | 34,602 | $2.89 | $99,999.78 |
DisclosureSEC source: 0001209191-20-062750 · doc4.xml · nonDerivative · entry 1 Galindo Alejandro · CIK 0001821447 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,602 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.